Abstract
There is minimal to no data regarding the use of SBRT as definitive primary treatment in other head & neck disease sites. Limited data support the use of brachytherapy or SBRT as a boost to EBRT in the definitive setting for nasopharyngeal (Chap. 1), paranasal sinus, and oropharyngeal SCC.
-
Generally indicated for T1-2 tumors.
-
Efficacy and complication rates are similar between brachytherapy and SBRT.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Al-Mamgani A, Van Rooij P, Sewnaik A, et al. Brachytherapy or stereotactic body radiotherapy boost for early-stage oropharyngeal cancer: comparable outcomes of two different approaches. Oral Oncol. 2013;49:1018–24.
Lee DS, Kim YS, Cheon JS, et al. Long-term outcome and toxicity of hypofractionated stereotactic body radiotherapy as a boost treatment for head and neck cancer: the importance of boost volume assessment. Radiat Oncol. 2012;7:85.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Judy, G.D., Chera, B.S. (2018). Other Head and Neck Sites. In: Kaidar-Person, O., Chen, R. (eds) Hypofractionated and Stereotactic Radiation Therapy. Springer, Cham. https://doi.org/10.1007/978-3-319-92802-9_12
Download citation
DOI: https://doi.org/10.1007/978-3-319-92802-9_12
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-92800-5
Online ISBN: 978-3-319-92802-9
eBook Packages: MedicineMedicine (R0)